One dose of TAF every three days gets more drug into cells than a daily dose of TDF
Dolutegravir more likely to suppress very high viral loads than other recommended first-line drugs
Treatment interruption in cure research is associated with greater risk of non-AIDS related events in the long term, Spanish study finds
Dolutegravir-based regimens result in sustained viral suppression, despite lower adherence and treatment interruptions
HIV vaccines and immunotherapies “would be further along” if they had the resources of COVID-19, says leading antibody researcher
Potent new anti-HIV drug only needs to be injected once every six months
Novel dual antibody therapy partially controls virulent HIV infection in monkeys off treatment
Studies confirm that hormone levels in trans women are not greatly affected by PrEP, or vice versa
Earlier treatment and higher CD4 counts linked to smaller HIV reservoir
